Searched over 200M research papers for "atenolol atenolol"
10 papers analyzed
Some studies suggest atenolol effectively lowers blood pressure, improves angina symptoms, and is well-tolerated, while other studies indicate it may not be suitable for hypertensive patients due to higher mortality and stroke risk.
20 papers analyzed
Atenolol is a selective beta 1-adrenoceptor antagonist, commonly known as a beta-blocker, with a duration of activity lasting at least 24 hours. It is primarily used in the management of cardiovascular conditions such as hypertension, angina pectoris, and certain arrhythmias .
Atenolol has been extensively studied and proven effective in reducing blood pressure across various patient demographics, including elderly patients and pregnant women with hypertension . Comparative studies have shown that atenolol lowers blood pressure to a similar extent as other beta-blockers, ACE inhibitors, calcium antagonists, and other antihypertensive agents . In a double-blind trial, atenolol significantly reduced blood pressure levels compared to bendrofluazide, and the combination of both drugs resulted in an even greater reduction.
Atenolol is effective in the prophylactic management of angina pectoris. Its long duration of beta-blocking activity allows for once-daily dosing, which is advantageous over other beta-blockers that require multiple doses per day. Studies have shown that atenolol significantly reduces the frequency and severity of anginal attacks and improves exercise tolerance in patients with angina.
Early intervention with intravenous atenolol followed by oral maintenance therapy has been shown to reduce infarct recurrence and cardiovascular mortality in patients with myocardial infarction . Additionally, atenolol is used to prevent the recurrence of supraventricular arrhythmias once control is achieved through intravenous administration.
Atenolol is generally well tolerated, with a side effect profile similar to other beta-blockers. Common side effects include cold extremities, fatigue, and diarrhea, but it has a lower incidence of central nervous system effects compared to non-selective beta-blockers like propranolol due to its low lipid solubility and limited brain penetration . However, atenolol has been associated with metabolic abnormalities, such as increased plasma triglycerides and decreased insulin sensitivity, which may contribute to an increased incidence of diabetes in hypertensive patients.
While atenolol is effective in lowering blood pressure and managing angina, some studies have raised concerns about its efficacy in reducing cardiovascular morbidity and mortality compared to other antihypertensive drugs. Meta-analyses have shown that atenolol may be associated with higher mortality rates and a higher incidence of stroke compared to other antihypertensive treatments. This has led to questions about its suitability as a reference drug in hypertension trials.
Atenolol remains a well-established treatment option for hypertension, angina pectoris, and certain arrhythmias. It is effective and generally well tolerated, with a convenient once-daily dosing regimen. However, its potential metabolic side effects and comparative efficacy in reducing cardiovascular events warrant careful consideration when selecting antihypertensive therapy. Further research is needed to fully understand its long-term impact on cardiovascular health.
Most relevant research papers on this topic